Sustainability reporting for pharmaceutical companies–Best practices and insights
New reporting standards and rising stakeholder expectations are lifting the quality of sustainability reporting for pharmaceutical and medtech companies. But what does best practice look like?
8 May 2025 15:00
Our panelists
Christoffer Falkman
ESG Director
Bavarian Nordic
Helle Bjerring Becker
Manager, ESG Reporting
Novo Nordisk
Dr. Adrian Kyburz
Director of ESG Disclosures and Ratings
Novartis
Simon Taylor
Senior Director
Position Green
Register below to join the webinar live
Join us for an exclusive discussion on best-practice sustainability reports from Novo Nordisk, Novartis and Bavarian Nordic, three leading pharma companies. We’ll dive into the reports with their ESG reporting leaders and discuss key insights and lessons learned.
What you’ll gain:
- Key insights from best practice pharmaceutical sustainability reports–Understand what worked well and how to incorporate it into your own reports.
- Lessons on reporting pharmaceutical-specific topics–Such as access to medicines, patient health and safety, ethical marketing and falsified medicines.
- Best practices for structuring and presenting your report–From materiality assessments to governance disclosures.
- Practical guidance for improving your 2025 sustainability report which you can apply immediately.
Date & time:
- 8 May
- 15:00–16:00 CEST / 14:00–15:00 BST / 09:00–10:00 EDT
